METABOLIC & WEIGHT RESEARCH / COLOPHON
About metabolixpeptides
A citation-anchored map of three peptides studied for metabolic regulation, at three very different evidence stages. Nothing sold, no one treated, no advice given.
What this desk covers
metabolixpeptides charts the published research on three peptides connected by one broad theme — metabolic regulation and weight management — approached from three structurally distinct directions: a receptor agonist, a hormone fragment, and a mitochondria-encoded signal. Each compound holds its own page; a comparison page lays the three side by side on mechanism, evidence stage, and regulatory status; and one shared references list gathers every source drawn on across the site.
A field this crowded, and this often overstated in marketing copy, needs a legible account of what is actually known. Each page states plainly what was studied, in whom, at what stage of development, and how far that evidence honestly reaches — which for these three compounds ranges from a decade of large, FDA-reviewed clinical trials down to mouse studies with no completed human trial at all. Holding that line, compound by compound, is the entire reason this site exists.
How the map is drawn
Every factual claim on this site carries a numbered citation traceable to a peer-reviewed article, a registered clinical-trial publication, or a dedicated safety review, gathered with DOIs and PubMed links on the references page. Where a finding comes from a large randomized trial in thousands of people, the page says so; where it comes from a mouse study, a small human cohort, or an observational database rather than a controlled trial, the page says that too, explicitly and without softening it.
Where a page reports how people describe their own experience with a compound — drawn from patient forums and research-community discussion — that material is always labeled as anecdotal, kept separate from the cited clinical literature, and never attached to a dose. For MOTS-c specifically, where no such community-reported body of experience exists in any substantial or verifiable form, this site says that plainly rather than filling the gap.
The edges of the map
metabolixpeptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. Nothing here is sold, sourced, or brokered, and no pharmaceutical company, supplier, or clinic pays for placement on any page. No clinician is on staff; nothing is diagnosed, and no dose, schedule, or route is ever named for any individual person.
Semaglutide is an approved prescription medicine, reachable only through a licensed provider. AOD-9604 is a discontinued drug candidate available legally, at present, only within the bounds of research use. MOTS-c is a research chemical with no completed human trial. Anyone seeking clinical guidance about any of these compounds should take that question to a licensed provider in their own jurisdiction. Corrections and citation notes are welcome via the contact page; requests for medical advice cannot be answered there.